



Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

March 25, 2021

Sent via E-mail: AGO.highcostprescriptiondrugs@vermont.gov

Subject: New Drug Introduction Notification pursuant to 18 V.S.A. § 4637(b)

To the Office of the Attorney General of Vermont.

Pursuant to 18 V.S.A. § 4637(b), BioCryst Pharmaceuticals, Inc. ("BioCryst") hereby provides to the State of Vermont new drug notices for Rapivab® (NDC 72769-0181-03) and Orladeyo™ (NDC 72769-0101-01 and NDC 72769-0102-01).

- Rapivab (NDC 72769-0181-03) - (peramivir) injection, for intravenous use - became commercially available on September 15, 2020 at a Wholesale Acquisition Cost ("WAC") of \$950.00.
- Orladeyo (NDC 72769-0101-01 and NDC 72769-0102-01) - (berotralstat) capsules, for oral use - became commercially available on December 4, 2020 at a Wholesale Acquisition Cost ("WAC") of \$37,308.00.

If you have any further questions, please do not hesitate to contact me.

Regards,

A handwritten signature in black ink that reads "Joel Turner".

Joel Turner, MBA
Vice President, US Market Access & Patient Services

CELL 918.671-7757

EMAIL jturner@biocryst.com